Expert Point of View: Steven J. O’Day, MD


Get Permission

This is an important large retrospective single-institution study …[conducted in the context of a] tremendous increase in use of MRI for invasive and noninvasive breast cancer,” said Steven J. O’Day, MD, who moderated a presscast held just prior to the 2013 Breast Cancer Symposium.

“The study grounds us and shows us that we should be sure we are actually making a difference with the use of new technology. The authors are not saying that MRI can’t be used perioperatively or postoperatively, but they question its routine use in DCIS, because it is not an independent predictor of improving locoregional recurrence (LRR) or contralateral breast cancer (CBC) outcomes,” he added. Dr. O’Day is Director of Clinical Research at the Beverly Hills Cancer Center and Adjunct Member of the John Wayne Cancer Institute in Los Angeles.

Dr. O’Day called for additional prospective studies to establish the optimal role of MRI in ductal carcinoma in situ and invasive breast cancer. ■

Disclosure: Dr. O’Day reported no potential conflicts of interest.


Related Articles

Single-Institution Study Evaluates Routine Use of Perioperative MRI in Patients With Ductal Carcinoma In Situ

Perioperative MRI for patients with ductal carcinoma in situ (DCIS) was not associated with a reduction in locoregional recurrence or contralateral breast cancer development in a large single-center study reported at the 2013 ASCO Breast Cancer Symposium. The study also was presented at a...

Expert Point of View on ductal carcinoma in situ

In an e-mail interview, E. Shelley Hwang, MD, an expert who has coauthored several papers on ductal carcinoma in situ (DCIS), weighed in on the two abstracts about management of DCIS featured in this issue of The ASCO Post—one presented by Melissa L. Pilewskie, MD (perioperative MRI in DCIS, page...


Advertisement

Advertisement



Advertisement